Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECF/EOF/ECX/EOX trial in advanced oesophago-gastric cancer
ISRCTN51678883Phase 3Completed
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Mar 2000
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of epirubicin, cisplatin, oxaliplatin, fluorouracil and capecitabine in esophageal cancer, esophagogastric junction cancer and gastric cancer (GC) (4 arms), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoint: Overall survival. Started Mar 2000; status: completed.
02
Drugs
epirubicincisplatinoxaliplatinfluorouracilcapecitabine
03
Conditions
esophageal canceresophagogastric junction cancergastric cancer (GC)
Beyond the preview
Go deeper on ISRCTN51678883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN51678883.